Screener
ANI Pharmaceuticals ANIP Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Net Revenues by Business | ||||||
| Generics and Other | $100.66M+6.8% | $109.22M+6.0% | $103.49M+23.7% | $98.69M+19.3% | $94.21M+19.5% | |
| Rare Disease and Brands | $165.39M+41.2% | $128.24M+36.3% | $143.57M+34.3% | $129.13M+96.8% | $117.16M+97.8% | |
| Net Revenues by Product | ||||||
| Brand royalties and other revenues | $17.73M— | $21.54M— | —— | —— | $0— | |
| Brands | $11.81M-10.5% | $12.33M-50.9% | $12.32M-37.9% | $10.68M+16.1% | $13.2M+31.6% | |
| Cortrophin Gel | $117.13M+43.5% | $75.12M+42.1% | $111.43M+87.6% | $101.85M+93.8% | $81.65M+66.0% | |
| Generic pharmaceutical products | $99.05M+9.7% | $105.4M+6.8% | $100.76M+28.2% | $94.38M+20.6% | $90.3M+22.1% | |
| ILUVIEN and YUTIQ | $18.72M-16.1% | $19.26M+19.5% | $19.84M-28.2% | $16.6M+329% | $22.32M— | |
| Other generic revenues | $1.61M-59.0% | $3.82M-12.5% | —— | —— | $3.92M— |
FAQ
- How does ANI Pharmaceuticals break its business down?
- ANI Pharmaceuticals (ANIP) reports net revenues by business across 2 parts — Generics and Other and Rare Disease and Brands. Each is extracted from the segment footnotes and tracked over time.
- Where does ANI Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ANI Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
